iMEA : Comparison of Micro-innervation and Muscle Microstructure of the Anal Levator Muscle Between Patients With Urogenital Prolapse and Those Who Are Asymptomatic

NCT ID: NCT03947164

Last Updated: 2025-06-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-17

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pelvic organ prolapse (POP) is defined by the International Continence Society (ICS) as a downward displacement of one or several of the followings: "the anterior wall of the vagina", "the posterior wall of the vagina" or "the cervix".

Principal risk factor of the POP is the muscular trauma of the Levator Ani Muscle (LAM) or pelvic nerve injury during vaginal delivery and pregnancy. The POP is a real public health problem. Nearly a quarter of the female population will be affected by this pathology during their lifetime. Also, the POP is responsible for impaired quality of life. POP management is mainly surgical. The LAM is classically described as a striated muscle. In an anatomic study based on female human fetuses, it has been described a new representation of nerve supplying LAM innervation with both autonomic and somatic participation. In a second study, it has been observed within the LAM, a visceral medial area (interface with the pelvic viscera) composed of smooth muscle cells under autonomic nervous control and a lateral parietal area (interface with the bone basin) composed of striated muscle cells under somatic control. Because of the medial localization of these smooth muscle areas, it is hypothesed that the visceral medial zone within the LAM plays a major role in pelvic status maintaining.

The main goal is to compare the proportion of smooth muscle cells within the MEA in patients with urogenital prolapse and in asymptomatic ones.

The secondary objectives are:

* To compare the expression of neurotransmitters within smooth muscle cell areas in patients with POPs and asymptomatic patients.
* To compare the proportion of striated muscle cells in MEA in patients with POPs and asymptomatic patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is a monocentric case-control study (1: 1). The inclusion of cases and witnesses will be prospective. For each case, a witness will be included with matching on parity (0, at least one child). Concerning the age, they will be matched according to the following age groups: 18-39 years old, 40-44 years old, 45-49 years old, 50-54 years old, over 55 years old.

For cases and controls, before the intervention, a questioning (age, weight, height, parity, mode of delivery, hormonal status), clinical symptoms of POPs and urinary incontinence, a detailed clinical examination, and an urodynamic assessment (in case of POPs) will be noted.

All cases and controls will have an ultrasound guided MEA biopsy. A fine needle will be used. The biopsy (5mm) will interest the medial part located between the vagina and the rectum.

Patients will be seen on post-operative visits between 15 days and 2 months after surgery for an examination and clinical examination.

From the biopsy, it will be performed a classic staining (Masson's trichrome) and specific immuno-markings to detect all the nerves, and to differentiate parasympathetic autonomic, sympathetic autonomic, erectile, and somatic nerves. Immunostaining for smooth muscle, striated muscle and relaxin system will also be performed. An immunofluorescence technique will be associated. Thus, some additional slides will be reserved for an actomyosin ATPase enzymatic reaction to differentiate muscle fiber types. Treated sections will be digitized with a Hamamatsu slide scanner for subsequent image analysis and analysis. The size of the different types of striated muscle fibers (1, 2a, 2b) will be measured using the NDPview (Hamamatsu) software. The labeling surface of the different antibodies will be quantified objectively by the NIS-Elements Viewer software.

Benefits are collective :

1. Clinical impact: Find new medical therapeutic targets and improve rehabilitation techniques.
2. Repercussion in research:

* To set up a PHRC with a randomized controlled multicenter study on the comparison of electrical stimulation and voluntary muscular contraction in postpartum with measurement of pelvic floor muscle strength and pelvic-perineal evaluation (search for pelvic prolapse , urinary incontinence).
* To improve knowledge of anatomy and physiology of pelvic floor muscles by mapping neurotransmitters in LAM in adult patients with POPs and asymptomatic patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prolapse Genital

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Monocentric case-control study (1: 1). The inclusion of cases and controls will be prospective. For each case, a control will be included with matching on parity (0, at least one child). Concerning the age, they will be matched according to the following age groups: 18-39 years old, 40-44 years old, 45-49 years old, 50-54 years old, over 55 years old.
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case group

Case :

\- Patient operated at Rennes University Hospital of anterior POP and / or posterior POP via vaginal and / or abdominal way.

POPs will be classified in stages 2-4 using the ICS classification;

* Without urinary incontinence associated effort (eliminated by the interrogation);
* Registered to a health insurance system;
* Having received information on the protocol and giving informed written consent.

Group Type OTHER

biopsy

Intervention Type OTHER

For cases and controls, before the intervention : a questioning, clinical symptoms of POPs and urinary incontinence, a detailed clinical examination, and an urodynamic assessment (in case of POPs) and an ultrasound guided MEA biopsy.

Patients will be seen on post-operative visits between 15 days and 2 months after surgery for an examination and clinical examination.

Control group

Control:

Patient operated at the Rennes University Hospital for a vaginal or abdominal hysterectomy for a benign reason.

* No POPs and no urinary incontinence eliminated during the interrogation and clinical examination.
* Registered to a health insurance system;
* Having received information on the protocol and giving informed written consent.

Group Type OTHER

biopsy

Intervention Type OTHER

For cases and controls, before the intervention : a questioning, clinical symptoms of POPs and urinary incontinence, a detailed clinical examination, and an urodynamic assessment (in case of POPs) and an ultrasound guided MEA biopsy.

Patients will be seen on post-operative visits between 15 days and 2 months after surgery for an examination and clinical examination.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

biopsy

For cases and controls, before the intervention : a questioning, clinical symptoms of POPs and urinary incontinence, a detailed clinical examination, and an urodynamic assessment (in case of POPs) and an ultrasound guided MEA biopsy.

Patients will be seen on post-operative visits between 15 days and 2 months after surgery for an examination and clinical examination.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Case :

\- Patient operated at Rennes University Hospital of anterior POP and / or posterior POP via vaginal and / or abdominal way.

POPs will be classified in stages 2-4 using the ICS classification;

* Without urinary incontinence associated effort (eliminated by the interrogation);
* Registered to a health insurance system;
* Having received information on the protocol and giving informed written consent.

Control :

For each case, a witness will be included with matching on the 5 year age group and parity (0, at least one child). It will be :

* Patient operated at the Rennes University Hospital for a vaginal or abdominal hysterectomy for a benign reason.
* No POPs and no urinary incontinence eliminated during the interrogation and clinical examination.
* Registered to a health insurance system;
* Having received information on the protocol and giving informed written consent.

Exclusion Criteria

* Pregnant or lactating women
* Patients with pelvic endometriosis, pelvic gynecological cancer, history of hysterectomy.
* Major person subject to legal protection (safeguard of justice, guardianship, tutorship), deprived of liberty.
* Participation in another research involving the interventional human person or at minimal risk and constraint
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rennes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

02.99.28.43.21 Nyangoh Timoh, MD

Role: PRINCIPAL_INVESTIGATOR

Rennes University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rennes University Hospital

Rennes, Brittany Region, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

35RC18_9793_iMEA

Identifier Type: OTHER

Identifier Source: secondary_id

2019-A00393-54

Identifier Type: REGISTRY

Identifier Source: secondary_id

35RC18_9793_iMEA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prenatal Pelvic Floor Prevention (3PN)
NCT00551551 COMPLETED PHASE3
Platelet Rich Plasma in Levator Ani Muscle Trauma
NCT03021954 COMPLETED PHASE2/PHASE3